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Objective: The treatment of acute, complicated type B aortic dissection has evolved in the past several decades. Thoracic
endovascular aortic repair when anatomy is suitable, has been regarded as the preferable treatment to seal the primary
entry tear, redirect and re-establish adequate true lumen ﬂow, and thereby promote aortic remodeling. This study was
designed to determine the safety and efﬁcacy of a conformable thoracic endoprosthesis device for patients with acute,
complicated type B aortic dissection, deﬁned as malperfusion or rupture or both.
Methods: Between January 2010 and January 2012, 50 patients with complicated type B aortic dissection from 26 sites in
the United States were included in this prospective, multicenter, nonrandomized single-arm study. The primary safety
end point was all-cause mortality through 30 days after treatment, and the primary efﬁcacy end point was exclusion of the
primary entry tear (Core Laboratory adjudicated) at 1-month follow-up. Secondary end points included false lumen
thrombosis, dissection-based reintervention rate, and aortic rupture.
Results: All device implants were successfully completed. Six patients (12%) required additional device implantations
#1 year from the index procedure. There was no conversion to open repair at 1 year. Exclusion of the primary entry tear
at 30 days occurred in 97.5% of patients. All-cause mortality through 30 days was 8%. Survival was 88% at 1 year and 85%
at 2 years. At 1 year after treatment, 35.1% of patients had experienced a decrease of $5 mm in overall diameter in the
treated segment of the aorta. From pretreatment to the 36-month follow-up, the average minimum true lumen area
increased by 206.3 mm2, and the average maximum false lumen area decreased by 313.4 mm2. The 30-day stroke rate was
18%; none were fatal, and one permanent deﬁcit occurred. Four patients (8%) experienced spinal cord ischemia of any
severity but without any permanent or signiﬁcant deﬁcits. New aortic dissection (3 retrograde, 2 de novo) occurred in ﬁve
patients (10%). The secondary intervention rate was 18%.
Conclusions: Treatment with the conformable thoracic endovascular aortic repair device produced favorable perioperative
and intermediate level clinical and anatomic outcomes. In particular, an operative mortality of 8% in this cohort is
comparable to that noted in a Society for Vascular Surgery objective performance criteria publication. Late survival in our
cohort compares favorably with historical data referable to complicated type B dissection. (J Vasc Surg 2015;62:271-8.)Stent graft repair (thoracic endovascular aortic repair
[TEVAR]) for acute type B dissection was ﬁrst described
by Dake et al1 and Nienaber et al2 in 1999 in companion
publications. In the ensuing 15 years, consensus on the
application of TEVAR for the various clinical scenarios in
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30% vs 10% mortality, respectively).3-5 Among the treat-
ment modalities applied to complicated type B dissection
during the past several decades, and supported in part by
trial data6,7 and collective reviews,8 the application of
TEVAR to seal the primary entry tear, thus preventing
rupture, and to redirect and re-establish adequate true
lumen ﬂow, thereby treating dynamic aortic branch
obstruction, has emerged as the preferred treatment mo-
dality. The availability of TEVAR, albeit applied until
recently as an off-label treatment, has clearly produced bet-
ter results than procedures such as open surgical or endo-
vascular fenestration.8,9 Furthermore, available data
referable to aortic remodeling after TEVAR for a type B
aortic dissection strongly suggest that such treatment will
also forestall the principle late complications of the disease,
namely, aneurysm formation.10,11
Recognizing the importance of pathology speciﬁc de-
vices, the sponsor for this study re-engineered the original
GORE TAG (W. L. Gore and Associates, Flagstaff, Ariz)
thoracic endovascular graft to a new design that was a
more conformable prosthesis with a much-improved
graft-to-aortic diameter ratio proﬁle. The current study
investigated the use of this redesigned prosthesis in the
management of acute, complicated type B dissection
deﬁned in this report as patients with rupture or signiﬁcant
malperfusion syndromes, or both.
METHODS
Study design. The GORE TAG 08-01 study was a
prospective, multicenter, nonrandomized, single-arm
study of 50 patients from 26 investigative sites in the
United States treated between January 2010 and January
2012. Study sites were required to have site-speciﬁc
Investigational Review Board review and approval, and all
participating sites were so approved.
The primary safety end point was all-cause mortality
through 30 days after treatment. The primary efﬁcacy
end point was exclusion of the primary entry tear at the
1-month follow-up visit as determined by Core Laboratory
analysis. Secondary efﬁcacy end points included false lumen
thrombosis adjacent to the stent graft (no thrombosis,
incomplete thrombosis, or complete thrombosis), reinter-
vention rate, and aortic rupture. Secondary interventions
of all types were recorded. A Clinical Events Committee
adjudicated clinical events. Other outcomes analyzed
included stroke, further aortic dissection events, and spinal
cord ischemic complications. Five-year study follow-up is
ongoing.
Patient eligibility. Patients aged between 18 and
80 years determined to have an acute, complicated type
B aortic dissection were included in the study. Inclusion
criteria included symptom onset to dissection diagnosis of
#14 days with TEVAR treatment #48 hours of diagnosis,
clinical or radiologic evidence, or both, of malperfusion
(visceral, renal, lower extremity, or spinal cord), rupture
in the setting of an aortic dissection (hemorrhage outside
of aortic boundaries), dissection distal to the left subclavianartery, treatment indication of “classic” aortic dissection
(aortic dissection with an intimal ﬂap between the true
and false lumen with double-barrel ﬂow in the thoracic
aorta and excluding class 2-5 lesions such as intramural
hematoma), and primary treatment as an endovascular
treatment with the Conformable GORE TAG device.
Adjunctive treatments may have included any or all of left
subclavian artery revascularization, percutaneous fenestra-
tion, aortic or peripheral vessel stenting, surgical fenestra-
tion, or peripheral artery bypass. Important primary
landing zone characteristics were mandated by protocol:
free of dissection, a length of $2.0 cm from the left
common carotid artery to the primary entry tear, and di-
ameters appropriate to the conformable thoracic endo-
prosthesis device. If necessary, left subclavian artery
coverage could be performed.
Additional exclusion criteria included a prior repair of
the descending thoracic aorta, an infected aorta, or a severe
systemic infection. Also excluded were patients with persis-
tent refractory shock or bowel necrosis, as characterized by
direct or laboratory observations concurrent with
computed tomography (CT) ﬁndings of portal venous
gas, free intra-abdominal air, or pneumatosis intestinalis.
Patients exhibiting moderate to severe renal failure, as
deﬁned by a baseline creatinine level of $2.5 mg/dL, or
with tortuous or stenotic iliac or femoral arteries precluding
TEVAR were potentially excluded, but all such clinical de-
cisions were at the investigator’s discretion. Pregnant
women and individuals with syndromic conditions (eg,
Marfan) were also excluded. Procedural exclusions
included planned coverage of the left carotid or celiac ar-
teries with the TEVAR device or a planned endovascular
procedure involving alterations to the study device.
To evaluate patient eligibility, a protocol-deﬁned heli-
cal CT angiography scan, physical examination, and serum
creatinine level was required preoperatively for each
individual.
Device description and implantation procedure.
The Conformable GORE TAG thoracic endoprosthesis
consists of a ﬂexible, self-expanding endoprosthesis and a
delivery catheter. The endoprosthesis is constrained on the
leading end of the delivery catheter by a sewn deployment
sleeve. An expanded polytetraﬂuoroethylene sealing cuff is
attached over the stent at each end of the device. The
device is introduced through a speciﬁc introducer sheath.
Other technical aspects of the delivery system and
deployment mechanism are available online (http://www.
goremedical.com/tag/instructions/).
Patient follow-up. Follow-up visits occurred at 1, 6,
and 12 months after the initial procedure and annually
thereafter through 5 years. Each follow-up visit included
a physical examination, four-view chest X-ray imaging, a
helical CT angiography of the chest, abdomen, and pelvis,
and an assessment for adverse clinical and device-related
events.
Data analysis. The current study is of a Bayesian adap-
tive design. The sample size of the study was not prespeci-
ﬁed but rather was determined by primary end point
Table I. Baseline clinical features of study cohort
Variables No. (%) (N ¼ 50)
Medical history
Hypertension 47 (94)
Cigarette smoking 27 (54)
Hypercholesterolemia 16 (32)
Renal insufﬁciency 11 (22)
Chronic obstructive pulmonary disease 10 (20)
Cardiac arrhythmia 10 (20)
Diabetes mellitus 9 (18)
Coronary artery disease 7 (14)
Myocardial infarction 6 (12)
Cancer 5 (10)
Peripheral vascular disease 5 (10)
Stroke 5 (10)
Congestive heart failure 3 (6)
Coronary artery bypass graft 2 (4)
Cardiac surgery 2 (4)
Carotid disease 2 (4)
Prior aortic dissection 2 (4)
Abdominal aortic aneurysm 1 (2)
Paraplegia 1 (2)
Transient ischemic attack 1 (2)
Risk assessment











No cardiac disease 32 (64)
ASA, American Society of Anesthesiologists; NYHA, New York Heart
Association.
Table II. Distal extent of dissection
Distal extent of dissection No. (%) (N ¼ 50)
Descending thoracic aorta 5 (10)
Celiac 4 (8)
Superior mesenteric artery 1 (2)
Renal arteries 5 (10)
Inferior mesenteric artery 5 (10)
Iliac arteries 30 (60)
JOURNAL OF VASCULAR SURGERY
Volume 62, Number 2 Cambria et al 273(30-day mortality) results. Enrollment was judged to be
complete when the posterior probability of using the
existing sample size was sufﬁcient to meet the performance
goal (30-day mortality of 25%) as speciﬁed from literature
and Society of Vascular Surgery (SVS) master ﬁle sources.12
Statistical analyses were performed using SAS 9.2 soft-
ware (SAS Institute Inc, Cary, NC). All-cause mortality was
investigated by Kaplan-Meier analysis. Kaplan-Meier ana-
lyses for true and false lumen remodeling contain bars indi-
cating the 25th and 75th percentiles and lines to connect
median values. Unless otherwise noted, conﬁdence inter-
vals (CIs) exist as score intervals for categoric variables
and Wald intervals for continuous variables.
RESULTS
Twenty-six centers enrolled 50 patients between
January 2010 and January 2012 after 170 patients were
screened for eligibility. Of 120 screen failures, 80% were
related to anatomic or comorbidity considerations.
Periprocedural patient characteristics. The patient
population was 74% male, 56% Caucasian, and the mean
age was 57.1 years (range, 31-83 years). Table I outlines
other clinical features of the study cohort.
The median time from symptom onset to diagnosis was
0.4 days (range, 0.0-7.3 days), with 98% of patients appro-
priately diagnosed #1 week of symptom onset. Table II
outlines the known distal extent of the dissection as
assessed by the Core Laboratory. Note that the distal
extent of the dissection was the iliacs in 30 of 50 patients
(60%). All patients were treated for malperfusion or rupture
or both. Indications for treatment are reported in
Table III, with the largest treatment group being malperfu-
sion alone in 78%. The incidence of speciﬁc forms of mal-
perfusion is further detailed in Table III (multiple vascular
territories were involved in most patients).
All patients received general anesthesia for the proce-
dure. All device implants were successfully completed,
with intravascular ultrasound imaging used in 58%. The
proximal aortic diameter was a median of 31 mm (range,
24-42 mm). The mean degree of oversizing was 12.5%.
Mean treatment length of the descending aorta was
20.6 cm (range, 10-33 cm), with proximal ﬁxation sites
#2.0 cm (proximal or distal) of the left subclavian artery
in all patients. Left subclavian artery management is
detailed in Table IV. At the time of the initial treatment,
26 of 50 patients (52%) required additional procedures,
which included peripheral branch or aortic stenting in 28
(56%), surgical bypass in 4 (8%), endovascular fenestration
in 2 (4%), and adjunctive angioplasty in 5 (10%).
Additional device implants occurred in 12% (6 of 50) of
patients (Table V). Two implants occurred#30 days of the
original procedure, four implants occurred within the ﬁrst
year, and one implant occurred >1 year on postoperative
day 861 (Table V). Two separate implant procedures
were performed in one patient after the initial treatment;
one on postoperative day 49 for ﬂow in the false lumen
and the other on postoperative day 84 for worsening inter-
mittent chest pain.Operative (30-day) mortality occurred in four patients
(8%) and was related to a single case each of mesenteric
infarction (present on transfer to treating study institution),
retrograde dissection with intrapericardial rupture, persis-
tent type 1A endoleak with rupture, and (autopsy-proven)
massive pulmonary embolism on postoperative day 3. At
least one serious adverse event occurred postprocedure in
28 of the 50 patients (56%), with more than one event re-
ported in 17. Three adverse events of particular interest
were stroke, new aortic dissection events, and paraplegia/
paraparesis. Stroke or clinical suspicion thereof occurred
in 18% (9 of 50) of patients #30 days of the initial
Table III. Indications for treatment
Indication No. (%) (N ¼ 50)
Malperfusion only 39 (78)
Rupture only 9 (18)
Malperfusion and rupture 2 (4)
Total malperfusion 41 (82)
Visceral 15 (36.6)a
Renal 30 (73.2)
Lower extremity 18 (43.9)b
Spinal cord 3 (7.3)
a10 patients with varying degrees of abdominal pain.
b7 patients reported ischemic rest pain.
Table IV. Left subclavian artery (LSA) coverage or
revascularization (N ¼ 50)
LSA procedure
LSA coverage, No. (%)
None Partial Complete
None 14 (28) 8 (16) 19 (38)
Transposed 0 (0) 0 (0) 2 (4)
Bypassed 0 (0) 1 (2) 6 (12)
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Committee, which included two neurologists who also
assessed status at discharge and the effect of the stroke
on functional outcome. Among the nine stroke patients,
one death (not stroke related) occurred, complete recovery
at last follow-up was noted in 75%, and ultimate functional
outcome was not negatively affected in seven of eight sur-
viving patients.
New aortic dissection events occurred in 10% (5 of 50)
of patients and were retrograde dissection events from the
stent graft itself or de novo type A dissections (Table VI).
Spinal cord ischemia of any severity occurred in 8% (4 of
50) of patients without relation to left subclavian artery
coverage. One patient had a persistent leg monoparesis at
discharge, with full recovery #1 year. Three others had spi-
nal cord ischemia (two early, one delayed) that resolved af-
ter prompt insertion of a cerebrospinal ﬂuid (CSF) drain.
Thus, there were no signiﬁcant total paraplegia events,
even though a CSF drain was placed preoperatively in
only 11 patients (22%). Paraplegia developed in one patient
after a subsequent surgical thoracoabdominal aortic aneu-
rysm graft replacement 2 years after the index procedure.
The efﬁcacy end point of exclusion of primary entry
tear at 30 days occurred in 97.5% (39 of 40) of patients
by Core Laboratory adjudication. The secondary efﬁcacy
end point of false lumen thrombosis adjacent to the stent
graft is outlined in Table VII. At 1 and 2 years after treat-
ment, complete false lumen thrombosis in the stented
segment occurred in 75% of patients (Table VII). Aortic
rupture occurred in 4% (2 of 50) of patients, with one on
study day 0 and one on postoperative day 89. One was a
rupture in the distal descending thoracic aorta and was un-
related to the TEVAR device or the endovascularprocedure, and the other was a retrograde dissection
rupture of the ascending aorta (Table VI).
Late clinical events. The mean follow-up interval for
survival was 725 days (range, 0-1219 days). Fig 1 displays a
Kaplan-Meier graph of overall survival at 12 and
24 months. Survival was 88% (95% CI, 0.75-0.94) at 1 year
and 85% (95% CI, 0.71-0.93) at 2 years. Causes of late
deaths are detailed in Table VIII.
Late anatomic results. The mean follow-up interval
for anatomic remodeling was 647 days (range, 0-1217
days). Change in overall aortic diameter in the treated
segment of the aorta was recorded. At 12months, 54.1% (20
of 37) of patients experienced no change, 35.1% (13 of 37)
experienced a decrease of $5 mm, and 10.8% (4 of 37)
experienced an increase of$5 mm. At 24 months, 50% (13
of 26) of patients experienced no change, 38.25% (10 of 26)
experienced a decrease of $5 mm, and 11.5% (3 of 26)
experienced an increase $5 mm. Maximum and minimum
true and false lumen aortic remodeling up to 36 months is
displayed in Fig 2 (diameters) and Fig 3 (areas). The average
minimum true lumen area increased by 206.3 mm2, and the
averagemaximum false lumen area decreased by 313.4mm2
from pretreatment to 36 months.
Secondary interventions. At 1 year, there had not
been a conversion to open repair in the stented segment
for any patient. The secondary intervention rate was 18%,
with most of the secondary interventions occurring within
the ﬁrst 30 days. As outlined in Table IX, nine patients
underwent 13 procedures after the initial implantation of
the Conformable GORE TAG device.
DISCUSSION
This prospective, multicenter, nonrandomized, single-
arm study investigated the safety and efﬁcacy of the
Conformable GORE TAG device in treating patients
with acute, complicated, type B aortic dissection. The pri-
mary end points of the study demonstrated an all-cause
mortality of 8% and an exclusion of the primary entry
tear in 97.5% of patients through 30 days. Long-term sur-
vival was 88% at 1 year and 85% at 2 years. The primary
safety and efﬁcacy results reported are similar or better
than those reported by White et al12 in an SVS objective
performance criteria report of identical patients managed
with TEVAR. Furthermore, the overall results, in particular
the early mortality, represent a major improvement in a pa-
tient cohort where earlier reports detailed an initial 30%
mortality.3,5
All patients in the current study were treated for
malperfusion or acute rupture, or both. Studies with less
stringent inclusion criteria (eg, persistent pain, poor blood
pressure control) have detailed lower 30-day mortality than
reported here, with rates as low as 4%.7,8 Notable is the fact
that this study detailed patients quite similar to 98 patients
treated under ﬁve separate physician-sponsored investiga-
tional device exemption trials, and published by the SVS
Outcomes Committee.12 Another trial similar to the cur-
rent study investigating a different TEVAR device but
also restricted to acute, complicated type B dissection
Table V. Additional device implants in six patients
Postoperative day Device used/technique Reason for intervention
2 CTAG device/standard Open distal fenestration resulting in persistent ﬂow in false lumen
238 CTAG device/standard Type II endoleak, type 1A endoleak, enlarging false lumen
861 Abdominal stent graft Enlarging distal thoracic aorta due to persistent false lumen ﬂow
0 TAG device/chimney Retrograde dissection
49a CTAG device/standard Flow in false lumen
84a Abdominal stent graft Worsening intermittent chest pain
156 TAG device/abdominal debranching Expanding descending thoracic aortic aneurysm requiring repair
CTAG, Conformable GORE TAG (W. L. Gore and Associates, Flagstaff, Ariz).
aSame patient.
Table VI. Proximal aortic dissection events
Days postprocedure Event description Potential mechanism as determined by CEC
0 Retrograde dissection Iatrogenic at index procedurea
6 Retrograde ascending aortic dissection Procedural/device related
29 Retrograde type A aortic dissection Presumed device related
89 Rupture new type A dissection De novo type A
183 Pseudoaneurysm of ascending aorta related to de novo
type A tear 1 cm above sinotubular junction (diameter, 8-9 cm)
De novo type A
CEC, Clinical Events Committee.
aRelated to device delivery; a retrospective review of the intraprocedural angiogram indicated retrograde dissection was present before device deployment.
Table VII. Incidence of false lumen thrombosis adjacent
to the stent graft
Time after procedure No. (%)
1 month 41
Complete thrombosis 26 (63.4)
Partial thrombosis 13 (31.7)
No thrombosis 0 (0)
Unknown 2 (4.9)
12 months 38
Complete thrombosis 29 (76.3)
Partial thrombosis 6 (15.8)
No thrombosis 1 (2.6)
Unknown 2 (5.3)
24 months 36
Complete thrombosis 20 (74.1)
Partial thrombosis 6 (22.2)
No thrombosis 0 (0)
Unknown 1 (3.7) Fig 1. Survival at 12 and 24 months. The range bars show 95%
conﬁdence interval (CI).
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ported here.13
Despite the manifest improvement in overall results
with TEVAR for complicated type B dissection (compared
with open surgery or medical therapy), these critically ill
patients are prone to signiﬁcant procedure-related compli-
cations, and among these, neurologic complications (stroke
and spinal cord injury) and retrograde aortic dissection
ﬁgure prominently. It is intuitively logical that such compli-
cations would occur more frequently in the treatment of
complicated type B dissection (vs other pathologies)
related to aortic fragility, zone 2 proximal seal, and long-
segment descending thoracic aorta coverage, which istypically required, at least in cases of rupture. Furthermore,
a consensus has emerged that both of these complications
are signiﬁcantly diminished when TEVAR is performed in
the subacute (ie, 15-90 days) phase of the disease.7,11,12,14
However, a delayed therapy approach was not available to
the present study cohort.
In consideration of speciﬁc complications, our overall
18% stroke rate is at the upper limit of the range of stroke
reported in related studies.7,12,13 Not surprisingly, studies
detailing nonacute patients reported signiﬁcantly lower
stroke risk.8,11,14 Potentially confounding variables, such
as left subclavian artery coverage (despite the lack of any
Table VIII. Causes of late deaths
Days
postprocedure Cause of death
89 Rupture of de novo type A dissection
182 Acute myocardial infarction
539 Cardiopulmonary arrest with chronic obstructive
pulmonary disease as a contributing factor
1055 Renal cell carcinoma
Fig 2. Maximum (diameter) of true and false lumen remodeling
through 36 months after treatment. The range bars show the 95%
conﬁdence interval (CI).
Fig 3. Minimum (area) of true and false lumen remodeling
through 36 months after treatment. The range bars show the 95%
conﬁdence interval (CI).
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brain hemorrhage, and an atypical atherosclerotic arch
(present in one of our patients), clearly increased the stroke
risk in our patients. Fortunately, only two patients had per-
manent negative functional effect related to stroke.
Procedure-related retrograde aortic dissection or de novo
type A dissection, or both, during follow-up occurred in
10% of our patients, similar to other studies in comparable
patients.12,13 It is clear that this complication can occur
with any TEVAR construct and that patients being treated
for acute dissection are at signiﬁcantly higher risk compared
with other pathologies.15 Anatomic considerations of the
proximal seal zone, speciﬁcally, an adequate nondissected
aorta is an important consideration in avoiding this compli-
cation, which accounted for one death in the present study.
Spinal cord ischemic complications were infrequent in this
study despite a mean descending aorta coverage length of
20 cm and infrequent use of prophylactic CSF drainage.
Despite the predominant thought that TEVAR is
preferred for complicated type B dissection, the literature
base supporting this position contains but two randomized
trials, and these trials considered patients without immediate
life-threatening dissection complications. The ﬁrst of these,
the Investigation of Stent Grafts in Aortic Dissection
(INSTEAD) trial, by its design essentially excluded patients
with acute, complicated type B dissection, and because itsprimary end point was all-cause mortality at 1 year after
treatment, it failed to show an advantage for stent graft
repair over optimal medical therapy.11 Ironically, a recent
publication from the INSTEAD investigators indicated su-
perior late survival for TEVAR vs medically treated patients
who had undergone treatment for essentially uncomplicated
type B dissection.16 The recently published Acute Dissection
Stent Grafting or Best Medical Treatment (ADSORB) trial,
which had anatomically deﬁned end points, demonstrated
that favorable aortic remodeling is facilitated by TEVAR
compared with optimal medical therapy.17
The current study revealed favorable midterm out-
comes after TEVAR and superior late survival in patients
with complicated type B aortic dissection treated with
TEVAR compared with historical results seen with opti-
mum medical therapy alone.13,14,18,19 Late survival in the
current study was similar to an International Registry of
Acute Aortic Dissection study, with an all-cause survival
rate of 88% at 1 year and 85% at 2 years.14 In the study
of White et al,12 survival was 70.6% at 1 year. These ﬁnd-
ings are consistent with other studies that have shown su-
perior long-term survival in TEVAR-treated patients vs
medically treated patients.14,16,18 Although the option of
initial medical therapy was illogical in the patients in this
study, it is also well documented that aortic-related mortal-
ity is a continued threat after type B aortic dissection, even
when the initial course is without complications and med-
ical therapy is typically selected. Indeed, initial medical
treatment for acute type B aortic dissection will eventually
fail in nearly 60% of patients so treated at a mean follow-up
of 4.3 years.20
The appropriate consideration for causes of latemortality
has been (albeit indirectly) addressed in both a recently re-
ported study19 and in that of the INSTEAD investigations.16
Namely, Durham et al20 found that the preponderance of
late interventionswhen typeB dissection is treatedwithmed-
ical therapy are open aneurysm resections. Similarly, the
Table IX. Secondary interventions
Patient
Days
postprocedure Reason for intervention Type of intervention
1 2 Persistent ﬂow in false lumen resulting from large
fenestration distal to original device
Placement of additional TAG device
1 3 Persistent hemothorax Decortication procedure
2 1 Renal failure Fenestration of the septum dividing the two
aortic channels
1 Anuria Endarterectomy of both renal arteries
3 4 Stenosis in iliac artery Peripheral stenting
4 2 Intestinal infarction Resection of right colon
5 0 Compartment syndrome Fasciotomy of left lower extremity
2 Exploratory laparotomy with total abdominal colectomy
4 Excision of small bowel and abdominal cavity washout
6 6 Retrograde ascending aortic dissection Ascending aortic replacement
7 183 De novo type A tear 1 cm above sinotubular junction
(diameter 8-9 cm)
Ascending aortic replacement
8 676 Aneurysm development distal to thoracic endovascular
aortic repair
Open thoracoabdominal repair
9 861 Patent fenestrations contributing to false lumen growth
distal to previously placed CTAG
Abdominal stent graft cuff and iliac stent
graft limb
CTAG, Conformable GORE TAG (W. L. Gore and Associates, Flagstaff, Ariz).
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aortic-related mortality over time in medically treated type
B dissection, reporting an aorta-speciﬁc mortality of 6.9%
for TEVAR with optimal medical treatment vs 19.3% for
optimal medical treatment alone at 5 years.16
Although the present study focused on the treatment
of life-threatening, complicated acute type B dissection,
our secondary ﬁndings indicate that TEVAR for type B
dissection will have a positive effect on aortic remodeling
and ultimately reduce the risk for late aneurysm formation.
Conrad et al10 reviewed the 1-year aortic remodeling after
TEVAR for acute type B dissection and found that >90%
of patients had false lumen thrombosis across the stented
segment with no aneurysmal degeneration. Similar results
were seen in the INSTEAD trial, where 90% of patients
treated with TEVAR had at least partial false lumen throm-
bosis at 1 year, which was signiﬁcantly higher than the 19%
reported in the medically treated cohort.11
This early false lumen thrombosis likely contributes to
long-term stabilization of the aorta, because 79% of pa-
tients in the TEVAR arm of the INSTEAD trial showed
favorable remodeling at 5 years.16 The current study shows
a similar early aortic response to TEVAR, where all but one
patient had some degree of false lumen thrombosis at
1 year and only two patients (4%) required further inter-
vention for aortic growth in the unstented portion of the
descending thoracic aorta at 2 and 4 years after the initial
TEVAR procedure.
In the Study of Thoracic Aortic type B Dissection using
Endoluminal Repair (STABLE) trial, complete obliteration
of the false lumen occurred in 44% of patients at 2 years, with
some degree of thrombosis documented in all patients.
Expansion of the true lumen and stabilization of the aorta
was noted in most patients, because 74% had a total aortic
diameter that decreased or stayed the same over the sametime frame.21 In the current study, the maximum true
lumen diameter increased initially and stayed relatively sta-
ble over 36 months, with 90% of patients having a stable
aortic diameter at 2 years; however, the data reported here
are conﬁned to the stented aortic segment.
CONCLUSIONS
The present study corroborates a consensus that
TEVAR is the preferred treatment for acute, complicated
type B aortic dissection with improved late survival and
positive aortic remodeling. Yet, with the recent, more
broadly based United States Food and Drug Administra-
tion approval of TEVAR devices (for type B dissection),
the task of deﬁning the role of such therapy in so-called un-
complicated acute type B aortic dissection patients, and for
those patients with a dissection in the chronic phase of the
disease, is the next logical step. As a corollary of the recent
approval, the Food and Drug Administration, industry, and
the SVS Vascular Quality Initiative have partnered to study
the real-world use of TEVAR for type B aortic dissection.
AUTHOR CONTRIBUTIONS
Conception and design: RC, AP, JM
Analysis and interpretation: RC, MC, AM, MF, AP, SC,
VP, JM
Data collection: AM, MF
Writing the article: RC, MC, SC, JM
Critical revision of the article: RC, MC, AM, MF, AP, SC,
VP, JM
Final approval of the article: RC, MC, AM, MF, AP, SC,
VP, JM
Statistical analysis: Not applicable
Obtained funding: Not applicable
Overall responsibility: RC
JOURNAL OF VASCULAR SURGERY
278 Cambria et al August 2015REFERENCES
1. Dake MD, Kato N, Mitchell RS, Semba CP, Razavi MK, Shimono T,
et al. Endovascular stent-graft placement for the treatment of acute
aortic dissection. N Engl J Med 1999;340:1546-52.
2. Nienaber CA, Fattori R, Lund G, Dieckmann C, Wolf W, von
Kodolitsch Y, et al. Nonsurgical reconstruction of thoracic aortic
dissection by stent-graft placement. N Engl J Med 1999;340:1539-45.
3. Cambria RP, Brewster DC, Gertler J, Moncure AC, Gusberg R,
Tilson MD, et al. Vascular complications associated with spontaneous
aortic dissection. J Vasc Surg 1988;7:199-209.
4. Suzuki T, Mehta RH, Ince H, Nagai R, Sakomura Y, Weber F, et al.
Clinical proﬁles and outcomes of acute type B aortic dissection in the
current era: lessons from the International Registry of Aortic Dissection
(IRAD). Circulation 2003;108(Suppl 1):II312-7.
5. Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ,
Russman PL, et al. The International Registry of Acute Aortic
Dissection (IRAD): new insights into an old disease. JAMA 2000;283:
897-903.
6. Cambria RP, Crawford RS, Cho JS, Bavaria J, Farber M, Lee WA, et al.
A multicenter clinical trial of endovascular stent graft repair of acute
catastrophes of the descending thoracic aorta. J Vasc Surg 2009;50:
1255-64.
7. Lombardi JV, Cambria RP, Nienaber CA, Chiesa R, Teebken O,
Lee A, et al. Prospective multicenter clinical trial (STABLE) on the
endovascular treatment of complicated type B aortic dissection using a
composite device design. J Vasc Surg 2012;55:629-40.
8. Eggebrecht H, Nienaber CA, Neuhäuser M, Baumgart D, Kische S,
Schmermund A, et al. Endovascular stent-graft placement in aortic
dissection: a meta-analysis. Eur Heart J 2006;27:489-98.
9. Lauterbach SR, Cambria RP, Brewster DC, Gertler JP,
Lamuraglia GM, Isselbacher EM, et al. Contemporary management of
aortic branch compromise resulting from acute aortic dissection. J Vasc
Surg 2001;33:1185-92.
10. Conrad MF, Crawford RS, Kwolek CJ, Brewster DC, Brady TJ,
Cambria RP. Aortic remodeling after endovascular repair of acute
complicated type B aortic dissection. J Vasc Surg 2009;50:510-7.
11. Nienaber CA, Rousseau H, Eggebrecht H, Kische S, Fattori R,
Rehders TC, et al. Randomized comparison of strategies for type B
aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissec-
tion (INSTEAD) trial. Circulation 2009;120:2519-28.
12. White RA, Miller DC, Criado FJ, Dake MD, Diethrich EB,
Greenberg RK, et al. Report on the results of thoracic endovascularaortic repair for acute, complicated, type B aortic dissection at 30 days
and 1 year from a multidisciplinary subcommittee of the Society for
Vascular Surgery Outcomes Committee. J Vasc Surg 2011;53:
1082-90.
13. Bavaria JE, Brinkman W, Hughes GC, Khoynezhad A, Szeto WY,
Azizzadeh A, et al. Outcomes of TEVAR in acute type B aortic
dissection: results from the Valiant US-IDE study. Presented at: 50th
Annual Meeting of the Society of Thoracic Surgeons, January 27,
2014, Orlando, FL.
14. Fattori R, Montgomery D, Lovato L, Kische S, Di Eusanio M, Ince H,
et al. Survival after endovascular therapy in patients with type B aortic
dissection: a report from the International Registry of Acute Aortic
Dissection (IRAD). JACC Cardiovasc Interv 2013;6:876-82.
15. Canaud L, Ozdemir BA, Patterson BO, Holt PJ, Loftus IM,
Thompson MM. Retrograde aortic dissection after thoracic endovas-
cular aortic repair. Ann Surg 2014;260:389-95.
16. Nienaber CA, Kische S, Rousseau H, Eggebrecht H, Rehders TC,
Kundt G, et al. Endovascular repair of type B aortic dissection: long-
term results of the randomized investigation of stent grafts in aortic
dissection trial. Circ Cardiovasc Interv 2013;6:407-16.
17. Brunkwall J, Kasprzak P, Verhoeven E, Heijmen R, Taylor P. Endo-
vascular repair of acute uncomplicated aortic type B dissection pro-
motes aortic remodelling: 1 year results of the ADSORB trial. Eur J
Vasc Endovasc Surg 2014;48:285-91.
18. Hogendoorn W, Hunink MG, Schlösser FJ, Moll FL, Sumpio BE,
Muhs BE. Endovascular vs open repair of complicated acute type B
aortic dissections. J Endovasc Ther 2014;21:503-14.
19. Zeeshan A, Woo EY, Bavaria JE, Fairman RM, Desai ND,
Pochettino A, et al. Thoracic endovascular aortic repair for acute
complicated type B aortic dissection: superiority relative to conven-
tional open surgical and medical therapy. J Thorac Cardiovasc Surg
2010;140(6 Suppl):S109-15.
20. Durham CA, Wang L, Ergul EA, Aranson NJ, Patel VI, Cambria R,
et al. Natural history of medically-managed acute type B aortic dis-
sections [published online ahead of print February 3, 2015]. J Vasc
Surg. http://dx.doi.org/10.1016/j.jvs.2014.12.038.
21. Lombardi JV, Cambria RP, Nienaber CA, Chiesa R, Mossop P,
Haulon S, et al. Aortic remodeling after endovascular treatment of
complicated type B aortic dissection with the use of a composite device
design. J Vasc Surg 2014;59:1544-54.
Submitted Jan 21, 2015; accepted Mar 5, 2015.
